Terencio, MC.; Ferrandiz, ML.; Carceller, C.; Ruhi, R.; Dalmau, P.; Verges, J.; Montell, E.... (2016). Chondroprotective effects of the combination chondroitin
sulfate-glucosamine in a model of osteoarthritis induced by anterior
cruciate ligament transection in ovariectomised rats. Biomedicine & Pharmacotherapy. 79:120-128. https://doi.org/10.1016/j.biopha.2016.02.005
Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/192890
Title:
|
Chondroprotective effects of the combination chondroitin
sulfate-glucosamine in a model of osteoarthritis induced by anterior
cruciate ligament transection in ovariectomised rats
|
Author:
|
Terencio, María Carmen
Ferrandiz, María Luisa
Carceller, Carmen
Ruhi, Ramón
Dalmau, Pere
Verges, Josep
Montell, Eulalia
Torrent, Anna
Alcaraz, María José
|
Issued date:
|
|
Abstract:
|
[EN] Context: The efficacy of the combination chondroitin sulfate-glucosamine (CS-GlcN) in the treatment of
knee osteoarthritis (OA) has been suggested in recent clinical studies. In vitro reports have also suggested
ant ...[+]
[EN] Context: The efficacy of the combination chondroitin sulfate-glucosamine (CS-GlcN) in the treatment of
knee osteoarthritis (OA) has been suggested in recent clinical studies. In vitro reports have also suggested
anti-inflammatory and anti-resorptive effects of this combination.
Objective: The aim of this study was to characterize the effects of CS-GlcN on joint degradation in vivo
including the assessment of inflammation and bone metabolism in a model of OA.
Materials and methods: We have used the OA model induced by anterior cruciate ligament transection
(ACLT) in ovariectomised rats. CS-GlcN was administered daily (oral gavage) from week 0 until week
12 after ovariectomy at the dose of 140 (CS) + 175 (GlcN)(HCl) mg/kg. Histochemical analyses were
performed, the levels of biomarkers and inflammatory mediators were measured by luminex or ELISA
and bone microstructure was determined by mCT.
Results: CS-GlcN protected against cartilage degradation and reduced the levels of inflammatory
mediators such as interleukin-1b and tumor necrosis factor-a in the affected knee. In addition, serum
biomarkers of inflammation and cartilage and bone degradation including matrix metalloproteinase-3,
C-telopeptide of type II collagen and the ratio receptor activator of nuclear factor kB ligand/
osteoprotegerin were significantly decreased by CS-GlcN. This treatment also tended to improve some
bone microstructural parameters without reaching statistical significance.
Discussion and conclusions: These results demonstrate the chondroprotective effects of CS-GlcN in vivo, in
the experimental model of ACLT in ovariectomised rats, and suggest that this combination may be useful
to control the joint catabolic effects of inflammatory stress. These
findings could have clinical relevance
related to the prevention of joint degradation by CS-GlcN and support the potential development of OA
treatments based on this combination.
[-]
|
Subjects:
|
Anterior cruciate ligament transection
,
Model
,
Osteoarthritis
,
Chondroitin sulfate-glucosamine
Ovariectomised rats
|
Copyrigths:
|
Cerrado |
Source:
|
Biomedicine & Pharmacotherapy. (issn:
0753-3322
)
|
DOI:
|
10.1016/j.biopha.2016.02.005
|
Publisher:
|
Elsevier
|
Publisher version:
|
https://doi.org/10.1016/j.biopha.2016.02.005
|
Project ID:
|
info:eu-repo/grantAgreement/MINECO//RD12%2F0043%2F0013/
|
Thanks:
|
The authors thank Ms. Anna Blanco for her technical assistance. The present study was supported by grants from Bioiberica S.A. and Spanish Ministerio de Economia y Competitividad, ISCIII, FEDER (RETICEF RD12/0043/0013). ...[+]
The authors thank Ms. Anna Blanco for her technical assistance. The present study was supported by grants from Bioiberica S.A. and Spanish Ministerio de Economia y Competitividad, ISCIII, FEDER (RETICEF RD12/0043/0013). The funding sources had no role in the conduct of the study; collection, management, analysis, interpretation of the data; and preparation of the manuscript. A.T., P.D., R.R., E.M. and J.V. are employed by Bioiberica S.A.
[-]
|
Type:
|
Artículo
|